We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

87 hedge funds and large institutions have $65.9M invested in Invesco Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 27 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 8787 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

0% less capital invested

Capital invested by funds: $66M → $65.9M (-$61.9K)

0.77% less ownership

Funds ownership: 21.39%20.61% (-0.77%)

37% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 27

Holders
87
Holders Change
Holders Change %
0%
% of All Funds
1.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
17
Reduced
27
Closed
9
Calls
$242K
Puts
Net Calls
+$242K
Net Calls Change
+$242K

PJP Hedge Fund Activity: Q2 2023 in Review

87 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2023, worth a combined $65.9M — down 0.09% from $66M a quarter earlier.

Fund positioning in PJP was balanced in Q2 2023: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 27 trimmed.

The largest buyer was Wells Fargo, adding an estimated $2.38M. The largest seller was Morgan Stanley, cutting an estimated $6.68M.

  • 87 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $65.9M of Invesco Pharmaceuticals ETF stock for Q2 2023, down 0.09% quarter-over-quarter.
  • 9 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2023 and 9 closed out, a net change of 0 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q2 2023 was Wells Fargo, an estimated $2.38M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q2 2023 was Morgan Stanley, an estimated $6.68M sold.

Based on aggregated 13F filings for Q2 2023.